RJA
FATE icon

Raymond James & Associates’s Fate Therapeutics FATE Stock Holding History

Raymond James & Associates’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-24,745
Closed -$250K – 3937
2022
Q4 		$250K Sell
24,745
-2,239
-8% -$42K ﹤0.01% 3323
2022
Q3 		$605K Sell
26,984
-2,831
-9% -$81.8K ﹤0.01% 2734
2022
Q2 		$739K Buy
29,815
+379
+1% +$10.5K ﹤0.01% 2651
2022
Q1 		$1.14M Buy
29,436
+8,790
+43% +$340K ﹤0.01% 2496
2021
Q4 		$1.21M Buy
20,646
+250
+1% +$14.2K ﹤0.01% 2497
2021
Q3 		$1.21M Buy
20,396
+355
+2% +$27.8K ﹤0.01% 2450
2021
Q2 		$1.74M Buy
20,041
+16
+0.1% +$1.29K ﹤0.01% 2193
2021
Q1 		$1.65M Sell
20,025
-2,934
-13% -$281K ﹤0.01% 2148
2020
Q4 		$2.09M Buy
22,959
+2,534
+12% +$157K ﹤0.01% 1868
2020
Q3 		$816K Sell
20,425
-925
-4% -$32.3K ﹤0.01% 2301
2020
Q2 		$733K Sell
21,350
-900
-4% -$26.8K ﹤0.01% 2346
2020
Q1 		$494K Sell
22,250
-11,997
-35% -$303K ﹤0.01% 2426
2019
Q4 		$670K Sell
34,247
-6,210
-15% -$98.6K ﹤0.01% 2526
2019
Q3 		$628K Buy
40,457
+5,819
+17% +$112K ﹤0.01% 2501
2019
Q2 		$703K Buy
34,638
+2,090
+6% +$37.7K ﹤0.01% 2430
2019
Q1 		$572K Buy
32,548
+5,110
+19% +$80.7K ﹤0.01% 2563
2018
Q4 		$352K Sell
27,438
-1,850
-6% -$25.8K ﹤0.01% 2770
2018
Q3 		$477K Buy
29,288
+2,085
+8% +$24.7K ﹤0.01% 2741
2018
Q2 		$308K Buy
27,203
+453
+2% +$4.99K ﹤0.01% 3006
2018
Q1 		$261K Buy
26,750
+3,725
+16% +$35.7K ﹤0.01% 2978
2017
Q4 		$141K Buy
+23,025
New +$103K ﹤0.01% 3149

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Raymond James & Associates's FATE Position: Q1 2023 in Review

Raymond James & Associates sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 24,745 shares — an estimated $250K sold.

Raymond James & Associates first reported a position in FATE in Q4 2017 and held it in 21 quarters. The position peaked at $2.09M in Q4 2020. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Raymond James & Associates reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Raymond James & Associates sold 24,745 Fate Therapeutics shares in Q1 2023, an estimated $250K.
  • Raymond James & Associates first reported a position in Fate Therapeutics in Q4 2017 and held it in 21 quarters.
  • Raymond James & Associates's Fate Therapeutics position peaked at $2.09M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.